Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis

【24h】

Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis

机译：在澳大利亚新辅助的患者环境中对Her2阳性非转移性乳腺癌的Pertuzumab研究：临时分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：在澳大利亚新辅助的患者环境中对Her2阳性非转移性乳腺癌的Pertuzumab研究：临时分析
2. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer [J] . Schneeweiss Andreas, Chia Stephen, Hickish Tamas, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018 ,第期

机译：随机，II期Tryphaena心脏安全研究的长期疗效分析：评估腹膜和曲妥珠单抗加上标准的新辅助蒽萘萘霉素和无蒽环类化疗中的Her2阳性早期乳腺癌
3. Myocet or carboplatin as part of chemotherapy in HER2-positive operable breast cancer treated with trastuzumab and pertuzumab in the neoadjuvant setting: Efficacy data and cardiotoxicity in 60 patients diagnosed from 2016-2019 at a single institution [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：Myocet或Carboplatin作为在Neoadjuvant环境中用曲妥珠单抗和Pertuzumab治疗的Her2阳性可操作的乳腺癌中的化疗的一部分：60例患者在2016 - 2019年诊断的60名患者中的疗效数据和心脏毒性
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Biomarker analysis of the NeoSphere study: pertuzumab trastuzumab and docetaxel versus trastuzumab plus docetaxel pertuzumab plus trastuzumab or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛用于HER2阳性乳腺癌的新辅助治疗
7. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer [O] . 2017

机译：NeoSphere研究的生物标志物分析：帕妥珠单抗，曲妥珠单抗和多西他赛与曲妥珠单抗加多西他赛，帕妥珠单抗加曲妥珠单抗或帕妥珠单抗加多西他赛对HER2阳性乳腺癌的新辅助治疗

Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis

著录项

相似文献

相关主题

期刊订阅